- GSK269962A
-
- $36.00
-
2026-05-11
- CAS:850664-21-0
- Purity: 99.65%
- Supply Ability: 10g
- GSK269962A
-
- $1.10
-
2025-06-25
- CAS:850664-21-0
- Min. Order: 1g
- Purity: 99.0% min
- Supply Ability: 100 tons min
|
| | GSK269962A Basic information |
| Product Name: | GSK269962A | | Synonyms: | GSK 269962;N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide;GSK269962A(GSK269962);CS-1126;N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]benzamide;ROCK inhibitor GS269962A;GSK 269962A;GSK-269962A;GSK269962;GSK 269962;GSK-269962;GSK269962B | | CAS: | 850664-21-0 | | MF: | C29H30N8O5 | | MW: | 570.6 | | EINECS: | | | Product Categories: | | | Mol File: | 850664-21-0.mol |  |
| | GSK269962A Chemical Properties |
| Melting point | 125 - 127°C | | density | 1.45 | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 13.19±0.70(Predicted) | | color | Off-White |
| | GSK269962A Usage And Synthesis |
| Description | Two Rho-associated kinases (ROCKS), ROCK1 and ROCK2, act downstream of the G protein Rho to regulate cytoskeletal stability. The ROCKs play important roles in diverse cellular functions including cell adhesion and proliferation, smooth muscle contraction, and stem cell renewal. GSK269962 is a selective ROCK inhibitor with IC50 values of 1.6 and 6 nM for ROCK1 and ROCK2, respectively. It displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. GSK269962 has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC50 = 35 nM). Oral administration of 1-30 mg/kg GSK269962 can dose-dependently lower blood pressure in spontaneously hypertensive rats. | | Uses | GSK 269962 is a potent and selective Rho kinase (ROCK) inhibitor. | | in vivo | GSK269962A is a potent antihypertensive agent. GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial[1]. | Animal Model: | Male Sprague-Dawley rats (350-400g)[1] | | Dosage: | 0.3, 1, and 3 mg/kg | | Administration: | Oral gavage; 12 hours | | Result: | Induced a dose-dependent reduction in blood pressure. |
| | IC 50 | ROCK1: 1.6 nM (IC50); ROCK2: 4 nM (IC50); RSK1: 132 nM (IC50); MSK1: 49 nM (IC50); AKT1: 955 nM (IC50); AKT2: 1350 nM (IC50); AKT3: 1510 nM (IC50); CDK2: 3500 nM (IC50); GSK3α: 1260 nM (IC50) | | storage | Store at +4°C | | References | [1] CHRIS DOE. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.[J]. Journal of Pharmacology and Experimental Therapeutics, 2007, 320 1: 89-98. DOI: 10.1124/jpet.106.110635 |
| | GSK269962A Preparation Products And Raw materials |
|